Electron deficient, bivalent sulfur atoms have two areas of positive electrostatic potential, a consequence of the low-lying σ* orbitals of the C-S bond that are available for interaction with electron donors including oxygen and nitrogen atoms and, possibly, π-systems. Intramolecular interactions are by far the most common manifestation of this effect, which offers a means of modulating the conformational preferences of a molecule. Although a well-documented phenomenon, a priori applications in drug design are relatively sparse and this interaction, which is often isosteric with an intramolecular hydrogen-bonding interaction, appears to be underappreciated by the medicinal chemistry community. In this Perspective, we discuss the theoretical basis for sulfur σ* orbital interactions and illustrate their importance in the context of drug design and organic synthesis. The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermolecular interactions between ligand C-S σ* orbitals and proteins are illustrated.

The basis for unprecedented noncovalent bonding between anions and the aryl centroid of electron-deficient aromatic rings has been demonstrated by an ab initio study of the interaction between 1,3,5-triazine and the fluoride, chloride, and azide ion at the MP2 level of theory. Minima are also located corresponding to C[bond]H...X(-) hydrogen bonding, reactive complexes for nucleophilic attack on the triazine ring, and pi-stacking interactions (with azide). Trifluoro-1,3,5-triazine also participates in aryl centroid complexation and forms nucleophilic reactive complexes with anions. This novel mode of bonding suggests the development of new cyclophane-type receptors for the recognition of anions.

The redox siblings nitroxyl (HNO) and nitric oxide (NO) have often been assumed to undergo casual redox reactions in biological systems. However, several recent studies have demonstrated distinct pharmacological effects for donors of these two species. Here, infusion of the HNO donor Angeli's salt into normal dogs resulted in elevated plasma levels of calcitonin gene-related peptide, whereas neither the NO donor diethylamine͞NONOate nor the nitrovasodilator nitroglycerin had an appreciable effect on basal levels. Conversely, plasma cGMP was increased by infusion of diethylamine͞NONOate or nitroglycerin but was unaffected by Angeli's salt. These results suggest the existence of two mutually exclusive response pathways that involve stimulated release of discrete signaling agents from HNO and NO. In light of both the observed dichotomy of HNO and NO and the recent determination that, in contrast to the O2͞O 2 ؊ couple, HNO is a weak reductant, the relative reactivity of HNO with common biomolecules was determined. This analysis suggests that under biological conditions, the lifetime of HNO with respect to oxidation to NO, dimerization, or reaction with O2 is much longer than previously assumed. Rather, HNO is predicted to principally undergo addition reactions with thiols and ferric proteins. Calcitonin gene-related peptide release is suggested to occur via altered calcium channel function through binding of HNO to a ferric or thiol site. The orthogonality of HNO and NO may be due to differential reactivity toward metals and thiols and in the cardiovascular system, may ultimately be driven by respective alteration of cAMP and cGMP levels.Angeli's salt ͉ superoxide dismutase ͉ heme protein ͉ cGMP ͉ calcitonin gene-related peptide D uring the last two decades, discussion of the chemistry of nitric oxide (NO) in biological systems has primarily focused on the nitrosylation of heme proteins such as soluble guanylyl cyclase and the production of reactive nitrogen oxide species (RNOS) (1-3). The RNOS literature has largely been concerned with nitrogen dioxide (NO 2 ), dinitrogen trioxide (N 2 O 3 ), and peroxynitrite (ONOO Ϫ ), which are formed through reaction with molecular oxygen or superoxide (O 2 Ϫ ) (4-6). Recently, however, there has been increased interest in the one-electron reduction product of NO, nitroxyl (HNO͞NO Ϫ ; nitrosyl hydride͞nitroxyl anion). Of particular note are studies suggesting that oxidation of L-arginine by NO synthase (NOS) leads to production of nitroxyl rather than NO under certain conditions (7-10). In this light, elucidation of the chemical biology of nitroxyl has acquired new importance.Comparisons of the toxicological and pharmacological properties of nitrogen oxide donor compounds have revealed that NO and HNO in general elicit distinct responses under a variety of biological conditions. In vitro, HNO reacts with O 2 to generate potent oxidizing species capable of cleaving DNA, thereby augmenting oxidative damage (3, 11). The RNOS formed by NO autoxidation do not cause these cellular a...

Experimental and theoretical data are provided for a set of 11 pericyclic reactions of unsaturated hydrocarbons. Literature experimental data are evaluated and standardized to ∆H q 0K for comparison to theory. Hartree-Fock, MP2, CASSCF, CASPT2, density functional theory (B3LYP, BPW91, MPW1K, and KMLYP functionals), and CBS-QB3 transition-structure geometries, activation enthalpies and entropies, and reaction enthalpies and entropies for these reactions are reported and are compared to experimental results. For activation enthalpies, several density functionals rival CASPT2 and CBS-QB3 for closest agreement with experiment, while CASPT2 and CBS-QB3 provide the most accurate heats of reaction. Transition-structure geometries are reproduced well by all methods with the exception of the Cope rearrangement and cyclopentadiene dimerization transition structures.

KRASG12C has emerged as a promising target in the treatment of solid tumors. Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-“undruggable” target; however clinically viable inhibitors have yet to be identified. Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRASG12C to identify inhibitors suitable for clinical development. Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond. Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRASG12C inhibitor currently in phase I clinical trials (NCT03600883).

A potential of about ؊0.8 (؎0.2) V (at 1 M versus normal hydrogen electrode) for the reduction of nitric oxide (NO) to its one-electron reduced species, nitroxyl anion ( 3 NO ؊ ) has been determined by a combination of quantum mechanical calculations, cyclic voltammetry measurements, and chemical reduction experiments. This value is in accord with some, but not the most commonly accepted, previous electrochemical measurements involving NO. Reduction of NO to 1 NO ؊ is highly unfavorable, with a predicted reduction potential of about ؊1.7 (؎0.2) V at 1 M versus normal hydrogen electrode. These results represent a substantial revision of the derived and widely cited values of ؉0.39 V and ؊0.35 V for the NO͞ 3 NO ؊ and NO͞ 1 NO ؊ couples, respectively, and provide support for previous measurements obtained by electrochemical and photoelectrochemical means. With such highly negative reduction potentials, NO is inert to reduction compared with physiological events that reduce molecular oxygen to superoxide. From these reduction potentials, the pKa of 3 NO ؊ has been reevaluated as 11.6 (؎3.4). Thus, nitroxyl exists almost exclusively in its protonated form, HNO, under physiological conditions. The singlet state of nitroxyl anion, 1 NO ؊ , is physiologically inaccessible. The significance of these potentials to physiological and pathophysiological processes involving NO and O 2 under reductive conditions is discussed. N itric oxide (NO) is an endogenously generated species with a diverse array of biological functions (1). NO is one of the primary regulators of vascular tone, is involved in signal transduction in both the peripheral and central nervous system, and is an integral part of the immune response system associated with macrophage and neutrophil activation. More recently, NO has been proposed to be involved in the regulation of mitochondrial function (2, 3). Problems in NO homeostasis have been implicated in the development of a variety of diseases and disorders such as hypertension and atherosclerosis (4), diabetes (5), and many neurodegenerative diseases (6). NO is also thought to be a cytoprotective agent, capable of inhibiting radical-induced damage and oxidative stress (7). To understand the actions of NO as a physiological messenger and a cytotoxic or cytoprotective effector molecule, it is essential to understand its basic chemical interactions with biological systems and its metabolic fate.NO and its reduced derivative NO Ϫ (and͞or its conjugate acid, HNO) have very different chemical properties and display distinct and often opposite effects in cells. For example, HNO͞ NO Ϫ has been found to be toxic under conditions where NO is cytoprotective (8). HNO͞NO Ϫ reacts with O 2 to generate potent oxidizing species, capable of damaging DNA and causing cellular thiol depletion, whereas NO does neither under similar conditions (9-11). HNO has been found to be a thiophilic electrophile (12), readily capable of modifying cellular thiol functions (13,14), whereas NO reacts only indirectly with thiols. HNO͞NO Ϫ h...

We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Continued research investigation of the N-alkyl substituent of this series, focused in particular on a previously underutilized interaction in a shallow cleft on the MDM2 surface, led to the discovery of a one-carbon tethered sulfone which gave rise to substantial improvements in biochemical and cellular potency. Further investigation produced AMG 232 (2), which is currently being evaluated in human clinical trials for the treatment of cancer. Compound 2 is an extremely potent MDM2 inhibitor (SPR KD = 0.045 nM, SJSA-1 EdU IC50 = 9.1 nM), with remarkable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model (ED50 = 9.1 mg/kg).

The cover picture shows the process of hydrogen and helium insertion/expulsion which has been achieved for the first time with an open fullerene derivative (outlined in the background). The experimental activation barrier for helium decomplexation could be obtained and fully agrees with the calculated value (density functional theory). The barrier for H2 complexation/decomplexation is interestingly almost double that of helium, as illustrated by the energy diagram shown in the foreground. This difference arises from the larger, elongated surface of H2 undergoing greater van der Waals interaction at the transition state relative to that of helium, even though both atoms have the same radii. More about this process can be found in the article by Rubin, Houk, Saunders, Cross et al. on p. 1543 ff.